XARELTO Drug Patent Profile

When do Xarelto patents expire, and when can generic versions of Xarelto launch?

Xarelto is a drug marketed by Janssen Pharms and is included in two NDAs. There is one patent protecting this drug and three Paragraph IV challenges.

This drug has twenty-nine patent family members in twenty-five countries.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the rivaroxaban profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xarelto

A generic version of XARELTO was approved as rivaroxaban by LUPIN on March 3^rd, 2025.

Summary for XARELTO

International Patents:	29
US Patents:	1
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	92
Clinical Trials:	128
Patent Applications:	5,099
Drug Prices:	Drug price information for XARELTO
Drug Sales Revenues:	Drug sales revenues for XARELTO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XARELTO
What excipients (inactive ingredients) are in XARELTO?	XARELTO excipients list
DailyMed Link:	XARELTO at DailyMed

See drug prices for XARELTO

See drug sales revenues for XARELTO

Recent Clinical Trials for XARELTO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
VA Office of Research and Development	PHASE4
U.S. Food and Drug Administration (FDA)	PHASE4
Prof. Stavros Konstantinides, MD	PHASE3

See all XARELTO clinical trials

Pharmacology for XARELTO

Drug Class	Factor Xa Inhibitor
Mechanism of Action	Factor Xa Inhibitors

Paragraph IV (Patent) Challenges for XARELTO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XARELTO	Capsules	rivaroxaban	10 mg, 15 mg and 20 mg	022406	1	2022-06-17
XARELTO	Tablets	rivaroxaban	2.5 mg	022406	4	2018-11-19
XARELTO	Tablets	rivaroxaban	10 mg, 15 mg, and 20 mg	022406	8	2015-07-01

US Patents and Regulatory Information for XARELTO

XARELTO is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	XARELTO	rivaroxaban	FOR SUSPENSION;ORAL	215859-001	Dec 20, 2021	AB	RX	Yes	Yes
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-002	Nov 4, 2011	AB	RX	Yes	No	9,539,218*PED				Y
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-004	Oct 11, 2018	AB	RX	Yes	No
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-001	Jul 1, 2011	AB	RX	Yes	No	9,539,218*PED				Y
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-003	Nov 4, 2011	AB	RX	Yes	Yes	9,539,218*PED				Y

Expired US Patents for XARELTO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-001	Jul 1, 2011	7,592,339
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-002	Nov 4, 2011	7,592,339
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-004	Oct 11, 2018	7,585,860
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-001	Jul 1, 2011	7,585,860
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-003	Nov 4, 2011	7,585,860

EU/EMA Drug Approvals for XARELTO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Accord Healthcare S.L.U.	Rivaroxaban Accord	rivaroxaban	EMEA/H/C/005279Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.	Authorised	yes	no	no	2020-11-16
Mylan Ireland Limited	Rivaroxaban Viatris (previously Rivaroxaban Mylan)	rivaroxaban	EMEA/H/C/005600Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers. Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events. ------Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.-------Adults Prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.	Authorised	yes	no	no	2021-11-12
Bayer AG	Xarelto	rivaroxaban	EMEA/H/C/000944Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.	Authorised	no	no	no	2008-09-30

International Patents for XARELTO

See the table below for patents covering XARELTO around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	032436	OXAZOLIDINONAS SUBSTITUIDAS, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS, EL USO DE LAS MISMAS PARA LA FABRICACION DE MEDICAMENTOS, Y EL METODO PARA IMPEDIR LA COAGULACION SANGUINEA IN VITRO
Austria	289605
Australia	2004218729
Australia	2841401
Australia	775126

Supplementary Protection Certificates for XARELTO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1261606	91497	Luxembourg		91497, EXPIRES: 20230930
1261606	PA2008018	Lithuania		PRODUCT NAME: RIVAROXABANUM; REG. NO/DATE: EU/1/07/472/001-008 20080930
1261606	CA 2008 00050	Denmark		PRODUCT NAME: RIVAROXABAN OG DETS FARMACEUTISK ACCEPTABLE SALTE, HYDRATER, HYDRATER AF SALTENE OG PRODRUGS
1261606	300370	Netherlands
1261606	PA2008018,C1261606	Lithuania		PRODUCT NAME: RIVAROXABANUM; REGISTRATION NO/DATE: EU/1/07/472/001 - EU/1/08/472/008, 0080930

Last updated: June 23, 2026

Xarelto (rivaroxaban) Market Dynamics and Financial Trajectory: Patent/Exclusivity Timing, Competitor Pressure, and Revenue Outlook

Executive summary: Xarelto (rivaroxaban) has entered a post-peak phase dominated by generic and competitor share loss in the U.S. and Europe, margin compression from lower-price entrants, and ongoing mix shift across indications and dosing. The near-term revenue trajectory is driven by (1) ongoing generic penetration, (2) how quickly biosimilar-like substitution dynamics occur for DOACs, (3) payer contracting across major markets, and (4) remaining value pockets in higher-acuity or hospital-driven use. Patent and market exclusivity do not stop generic erosion; they mainly shape timing of entry and legal leverage windows, which have already largely closed in core markets. Commercial risk is concentrated in U.S. and EU where multiple rivaroxaban generics are established, while growth offsets are more likely from international expansion and indication-specific retention rather than new molecular IP.

---

What drives Xarelto (rivaroxaban) market share vs Eliquis and Pradaxa in 2026?

Xarelto’s market dynamics in the DOAC class are shaped less by clinical differentiation and more by formulary position, contracting mechanics, and switching cost behavior. Rivaroxaban and class peers (apixaban Eliquis, dabigatran Pradaxa) compete across overlapping indications: nonvalvular atrial fibrillation (NVAF), venous thromboembolism (VTE) treatment, and prophylaxis in orthopedic settings.

Key share drivers

• Payer formulary placement and step therapy: Net pricing moves with formulary access, not list price.
• Wholesale acquisition cost (WAC) vs net price gap: DOAC rebates expand with competitive entry.
• Institutional preference in hospitals: Perioperative and acute-care pathways can lock in short-term inertia.
• Switching behavior by indication: NVAF can exhibit stickiness; VTE and prophylaxis can swing with contracting.

Competitive set intensity

• Eliquis (apixaban) has maintained strong brand share and payer relationships in many U.S. markets.
• Pradaxa (dabigatran) faces structural substitution pressure from all generic DOAC availability.
• Xarelto now competes primarily against other DOACs plus rivaroxaban generics. Once a generic is entrenched, incremental brand retention is mostly payer-specific.

---

How long did Xarelto keep exclusivity and when did generics accelerate?

Xarelto’s exclusivity timeline in major markets has already progressed through the key phases: brand launch protection, regulatory exclusivity overlays, then post-expiration generic entry. The practical revenue inflection came when multiple approved generic products reached meaningful market distribution, creating sustained downward pressure on net price.

Revenue impact pattern

• First, patent and exclusivity protected the brand pricing environment.
• Next, first-wave generics introduced market competition with partial penetration.
• Then, broad retail and payer adoption of generics drove a step down in net revenue per script.
• The later phase is “contracting-driven”: brand volume can persist, but price and net realization continue to erode.

Commercial takeaway The post-expiration period generally becomes durable because DOAC demand is “high convenience and high switchability” once payers set an economic preferred tier.

---

What patents and exclusivity (Orange Book) historically protected Xarelto, and what does that mean for generic risk?

For a small-molecule marketed as a fixed-dose oral anticoagulant, the patent estate typically spans:

• the active ingredient and core composition claims,
• crystalline or polymorph-specific forms,
• manufacturing/process claims,
• formulation and dosing regimens,
• method-of-use for specific indications or dosing schedules,
• and line extensions.

How that affects generic risk

• Early entry depends on the ability to invalidate or work around the most relevant claims.
• Later entry still occurs once at-risk claims expire, even if line-extension patents remain.
• For established molecules, generic viability increasingly hinges on whether any remaining formulation or method-of-use patents block label scope or dosage strength substitution, not whether generic rivaroxaban is “technically possible.”

Practical framing As of the current market structure, generic presence is already established in core segments, so litigation leverage mostly influences timing of specific label modifications or new dosage forms rather than stopping overall erosion.

---

How many Xarelto-related patent families are relevant to revenue, and which claim types matter most?

In mature DOAC markets, the claim types that affect revenue most are those that determine:

• whether a generic can market the same dosing strengths for the same indication, and
• whether payers treat the drug as interchangeable for contracted dosing regimens.

Claim types that matter commercially

• Method-of-use or dosing regimen claims: Delay a “fully substitutable” generic if label entry is constrained.
• Formulation/process claims tied to manufacturability: Can restrict supply ramp speed.
• Combination or extended release formulations: Typically fewer for DOACs; Xarelto is mainly an immediate oral dosing product, so this is less central than for other drug classes.

Where brand value can persist If remaining patents restrict the label or create at-risk launch uncertainties, brand volume can remain temporarily higher. Without such restrictions, price competition becomes the dominant factor.

---

What is the Orange Book status of Xarelto and how does that map to generic launches?

Orange Book status at the molecule level tends to correlate with:

• list of approved products for each strength,
• patent expiry dates,
• and whether there are active use patents still listed for relevant labels.

Market mapping

• When an Orange Book listing includes active patents for a specific use, generics must either wait or challenge via Paragraph IV.
• Once core patents expire, “all roads” lead to multi-source availability.
• In practice, with rivaroxaban, the competitive market indicates that the major blocking factors have already been resolved for core doses and indications.

---

What Paragraph IV challenges and settlements have historically affected Xarelto generics?

Paragraph IV litigation affects:

• the timing of first generic approvals for given strengths,
• potential 180-day exclusivity for the first challenger,
• settlement agreements that can delay subsequent entrants,
• and at-risk launch schedules.

Market reality lens Even with multiple rounds of litigation, once generics are widely approved and contracted, settlements often influence the calendar more than the ultimate long-run price level.

---

How does Xarelto’s biosimilar risk compare to biologics, and what replaces it in DOACs?

Xarelto is a small molecule. It does not face biosimilar pathways. The analog to “biosimilar risk” in DOACs is:

• generic substitution speed,
• payer tiering,
• and any residual label limitations driven by patent life.

So the risk is not data package similarity but market-level competitive equivalence and net pricing.

---

What formulations are protected for Xarelto, and do they change substitution economics?

Xarelto is an immediate oral anticoagulant with standard dosing strengths across key indications. Formulation patent scope tends to be narrower commercially than it is for complex dosage forms. Substitution economics typically depend on:

• dosing equivalence across strengths,
• interchangeability at the pharmacy level,
• and payer contracting.

Commercial impact Once multiple rivaroxaban generics cover the relevant strengths, formulation-level protection no longer changes the core substitution economics in most contracts.

---

How does Xarelto revenue change under switching from brand to generic (U.S. payer behavior)?

Revenue trajectory is dominated by net price realization and script volumes. Under generic switching:

• script counts can remain stable but net revenue per script collapses.
• manufacturer rebates decrease in relative terms once generics become preferred.
• brand share often stabilizes at a lower base driven by physician inertia, market segments with tighter clinical preferences, and specific payer exceptions.

Dominant mechanism In DOACs, payer contracting commonly sets the rate. The brand becomes a “brand premium,” which shrinks once generics get parity in coverage.

---

What does Xarelto’s financial trajectory look like by geography: U.S. vs EU vs ex-US?

U.S.

• Generally the highest penetration of multi-source rivaroxaban generics.
• Net revenue pressure is stronger due to payer aggressiveness and high competitive density.

Europe

• Similar erosion forces, often modulated by national procurement dynamics.
• Tendering and reimbursement policies determine the pace of generic adoption.

International / ex-US

• Brand retention can persist longer where generic density is lower or contracts lag.
• Growth depends on market penetration of rivaroxaban and competitive intensity entering each country.

---

How strong is the patent estate for Xarelto today, and what does that mean for incremental sales?

In mature small-molecule anticoagulants, the patent estate rarely produces meaningful incremental sales after broad generic entry. Remaining value can come from:

• any late-expiring method-of-use claims that restrict label scope for specific dosing regimens,
• manufacturing/process improvements that matter for supply reliability, or
• line-extension products (if any) that launch after core patent expiry but still benefit from remaining exclusivity.

For Xarelto specifically, the overall commercial environment indicates that most major value protections have already been consumed by generic competition, making incremental sales more dependent on contracting and indication management than IP-driven isolation.

---

Which companies are challenging Xarelto (rivaroxaban) the most, and where is price competition concentrated?

Price competition is concentrated among:

• generic manufacturers with established rivaroxaban portfolios, and
• large generic distributors with strong pharmacy and payer channel relationships.

In practice, competition intensity concentrates in:

• NVAF and VTE maintenance dosing equivalents,
• higher-volume strengths, and
• jurisdictions with aggressive generic switching.

Brand volume retention tends to concentrate in:

• payer exceptions,
• certain hospital systems, and
• patients with prior tolerance or clinician preference.

---

What generic entry risks exist for Xarelto across dosing strengths and indications?

Generic entry risk manifests as:

• launch of additional strengths,
• label-scope adjustments that allow broader substitution,
• and procurement tender cycles that replace brand or less-preferred generics.

Given the DOAC market maturity, the remaining risk is less “can a generic launch at all” and more:

• how fast new sources gain share,
• whether settlement calendars accelerate additional entrants,
• and whether any remaining label restrictions delay substitution for a subset of indications.

---

How does Xarelto compare with Eliquis on durability: brand retention, net pricing, and payer contracting?

Durability drivers

• Brand strength is correlated with payer relationships and the magnitude of net price discounts over time.
• Once generics flood both molecules, durability depends on:
  • which molecule retains a higher share of “preferred brand” positioning,
  • and which molecule has better negotiated economics.

Practical comparative conclusion In a world of widespread generics for both DOACs, the differentiation is mostly contractual and channel-specific rather than therapeutic. The brand with better payer access can show slower erosion, but neither is insulated from generic-led price pressure.

---

What manufacturing or IP barriers delay generic scale-up of rivaroxaban?

For small-molecule generics, barriers are usually:

• ability to produce consistent polymorph/form without quality drift,
• process validation and scale-up speed,
• supply chain capacity for multiple strengths,
• and regulatory data-package readiness for labeling and stability.

These barriers can temporarily affect availability and price, but they typically do not eliminate long-run substitution once multiple suppliers operate.

---

What key regulatory milestones and FDA pathway dynamics affect Xarelto’s competitive standing?

Xarelto’s regulatory milestones for competition are typically tied to:

• ANDA approvals for rivaroxaban strengths,
• suitability decisions and updates in labeling,
• and any changes to dosing, warnings, or indication wording that can trigger new substitution constraints.

In practice, once generics are broadly approved and therapeutically equivalent under FDA standards, the competitive standing shifts from regulatory gatekeeping to payer contracting.

---

How many years of revenue exposure remain for Xarelto given the DOAC generic landscape?

Revenue exposure is not a clean “years until zero” curve. Instead, it evolves through:

• gradual volume shifts to generics,
• periodic changes in payer preferred tiers,
• and new entrants replacing older suppliers.

In mature DOAC markets, the brand retains a residual base but continues to lose net revenue over time as contracts refresh. The remaining exposure tends to be driven by the pace of payer renegotiation in each geography.

---

Key tables: Xarelto revenue exposure model and competitive drivers

Table 1: Revenue sensitivity map (brand vs generic penetration)

Driver	Direction of impact on Xarelto net revenue	Why it moves
Generic penetration rate	Negative	More pharmacy substitution and payer preferred tiers shift to generics
Net price realization	Negative	Rebates compress as payers demand lower pricing
Script volume retention	Mixed	Some patients and prescribers stay on brand, but overall substitution reduces share
Indication mix	Mixed	NVAF can be stickier than some VTE prophylaxis segments
Geography contracting	Mixed	Some markets adopt generics slower due to tender cycles

Table 2: What matters most to litigation and launch calendars

IP lever	Affects launch timing?	Affects long-run share?
Composition/formulation patents	Often early	Moderate once multiple sources exist
Method-of-use and label scope patents	Can delay label coverage	Moderate if it blocks key substitutions
Manufacturing/process claims	Can delay supply	Low once capacity is scaled
Settlement calendars	Yes	Low to moderate after broader generic adoption

---

Key Takeaways

• Xarelto’s financial trajectory is primarily a function of DOAC class contracting and generic substitution, not incremental therapeutic differentiation.
• Patent/exclusivity timing has already shaped early entry and first-wave erosion; the current market environment is dominated by established generic competition.
• The main upside levers for residual brand performance are geography-specific contracting lags and indication-specific retention where payers or clinicians maintain brand positioning.
• The core downside is ongoing net price compression as payer preferences refresh across U.S. and major EU markets.

---

FAQs

How does Xarelto’s net price typically change after generic rivaroxaban entry?

Net price drops after payer conversion to lower-cost preferred tiers, even if prescription volume stays partially stable.

Which Xarelto indication is most vulnerable to generic substitution?

Indications with higher switching tolerance and procurement-driven prescribing patterns, often including prophylaxis segments, tend to be more vulnerable than certain NVAF cohorts.

Do settlements with generic applicants meaningfully slow Xarelto volume erosion?

Settlements can delay specific entrant launch dates, but they usually do not prevent long-run market conversion once multiple generics cover the main strengths and label uses.

What payer strategy reduces Xarelto brand losses?

Maintaining a negotiated “preferred brand” or controlled exception position in high-impact formularies can slow net revenue erosion.

How does Xarelto competition differ from biologics in terms of risk?

DOACs face generic substitution risk via ANDA approvals and payer tiers, not biosimilar interchangeability and extrapolation dynamics.

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. FDA. Drug Approval Reports and ANDA approval information for rivaroxaban products. FDA.

DrugChatter Q&A for XARELTO

When can we anticipate xarelto's patent to expire?
What's the xarelto patent expiration date?
Why is xarelto so expensive?
Xarelto financial trajectory?
When will the price of xarelto go down?